5-(4-Chlorobutyl)-1-cyclohexyl-1H-tetrazole is a chemical compound with the molecular formula C11H19ClN4. It consists of a tetrazole ring attached to a cyclohexyl group and a chlorobutyl chain. This compound is primarily used as an intermediate in the synthesis of cilostazol, a medication that treats intermittent claudication, which is a condition characterized by pain in the legs due to insufficient blood flow. Cilostazol functions as a phosphodiesterase III inhibitor, promoting vasodilation and preventing platelet aggregation, thus improving blood circulation and reducing the symptoms of intermittent claudication.
The discovery of 5-(4-chlorobutyl)-1-cyclohexyl-1H-tetrazole is not well-documented in the available literature. However, it has been studied extensively in the context of its use as a key intermediate in the synthesis of cilostazol. The compound's role in this synthesis makes it of significant interest in pharmaceutical research, particularly in the field of cardiovascular health. The structure of 5-(4-chlorobutyl)-1-cyclohexyl-1H-tetrazole provides a crucial building block for cilostazol, allowing for the development of the drug and its therapeutic applications.
The synthesis of 5-(4-chlorobutyl)-1-cyclohexyl-1H-tetrazole typically begins with the preparation of 5-chloro-N-cyclohexylpentanamide. This intermediate undergoes a series of reactions, including cyclization, to form the tetrazole ring structure. The process involves the use of reagents such as phosphorus pentachloride and azide sources, which facilitate the formation of the tetrazole and the attachment of the chlorobutyl group. The final product is purified and characterized for use in the synthesis of cilostazol.
In addition to its role in cilostazol production, 5-(4-chlorobutyl)-1-cyclohexyl-1H-tetrazole has not been widely explored for other applications in the literature. However, its structural features, such as the tetrazole ring and the chlorobutyl and cyclohexyl substituents, suggest that it may have potential in other areas of pharmaceutical chemistry, particularly in the development of other drugs targeting cardiovascular or metabolic conditions. The tetrazole ring, in particular, is a functional group found in a variety of bioactive molecules, which could make this compound a useful scaffold for drug design.
5-(4-chlorobutyl)-1-cyclohexyl-1H-tetrazole is typically handled with care due to the presence of the chlorobutyl group, which may have toxicological properties. Proper safety precautions are necessary when working with this compound in laboratory or industrial settings. It is recommended to use personal protective equipment, such as gloves and goggles, to avoid skin and eye contact. Additionally, inhalation of vapors should be prevented by working in a well-ventilated area or using a fume hood.
The compound has a melting point of 49–52°C and a boiling point of approximately 425.2°C at 760 mmHg. Its density is around 1.29 g/cm³. These physical properties indicate that 5-(4-chlorobutyl)-1-cyclohexyl-1H-tetrazole is a relatively stable compound under standard conditions. However, like many organic compounds, it may decompose under extreme conditions of heat or pressure.
In conclusion, 5-(4-chlorobutyl)-1-cyclohexyl-1H-tetrazole is an important intermediate in the production of cilostazol, a drug used to treat intermittent claudication. While its applications are primarily focused on the pharmaceutical industry, particularly in cardiovascular treatments, the compound's unique chemical structure and functional group characteristics suggest that it may have potential for further exploration in drug development.
References
none
Publication Name: Pharmaceutical Substances
Publication Date: 2003
|
GHS02;GHS07 Danger Details
Discovery and Applications